Factors Associated With Viral Suppression Among People Living With HIV (PLWH) in Kermanshah, Iran: A Retrospective Cohort Study Authors: Etrat Javadirad, Mosayeb Rostamian, Seyedeh Shadi Vaziri, Leila Solouki, Bahare Andayeshgar, Sepideh Khodamoradi, Roya Chegene Lorestani, Keyghobad Ghadiri Published: 2026 ABSTRACT ABSTRACTBackground and AimsDespite the expanded availability of antiretroviral therapy (ART), HIV remains a major global health challenge. Viral load (VL) is the main indicator used to assess treatment response, and viral suppression is the ultimate goal of therapy. However, virological response is influenced by various patient‐ and treatment‐related factors. This study aimed to identify factors associated with viral suppression among PLWH in Kermanshah, Iran.MethodsWe included 2909 PLWH attending the Kermanshah Behavioral Diseases Counseling Center between 2012 and 2023. Data on demographic, behavioral, and clinical characteristics, route of transmission, disease stage, clinic visits, CD4 counts, and VL were extracted from records. Due to the non‐normal distribution of VL, nonparametric tests (Spearman's correlation, Mann–Whitney U‐test, and Kruskal–Wallis) were used. Analyses were performed in SPSS v21, with p < 0.05 considered significant.ResultsAmong the 710 PLWH included in the analysis, 643 (90.6%) had viral suppression at the last available follow‐up VL measurement (VL < 200 copies/mL). In univariate analyses, sex, incarceration history, addiction history, injection drug use, marital status, occupation, clinical stage, route of HIV transmission, CD4 count, and duration of ART were significantly associated with viral suppression. In the multivariable logistic regression model, marital status, clinical stage, baseline CD4 count, and follow‐up CD4 count remained significantly associated with viral suppression after adjustment for the variables included in the model.ConclusionMost PLWH had viral suppression at the last follow‐up assessment. Disease stage, marital status, and follow‐up CD4 count were associated with viral suppression. These findings should be interpreted with caution because residual confounding cannot be excluded. Overall, the results highlight the importance of early HIV diagnosis, timely initiation of treatment, and sustained engagement in care to achieve optimal viral suppression. Introduction HIV infection remains a major global public health concern, with an estimated 39–40 million people living with HIV (PLWH) worldwide in recent years. Despite substantial progress in the scale‐up of antiretroviral therapy (ART), achieving the UNAIDS 95–95–95 targets continues to face significant challenges in many parts of the world. The Eastern Mediterranean region still lags behind other regions across the HIV care cascade, with lower rates of viral suppression compared to the global average. In contrast, regions such as Eastern and Southern Africa have demonstrated substantial progress in diagnosis, treatment coverage, and viral suppression rates. These findings highlight substantial gaps in HIV testing and treatment coverage in the Eastern Mediterranean region [1]. The low levels of HIV diagnosis and treatment coverage in these countries can be attributed to restrictive regulations, limited financial resources, ongoing crises such as war, restricted access to healthcare services for key populations, and a lack of accurate HIV surveillance data [1, 2]. Among the available indicators used to monitor HIV treatment outcomes, viral load (VL) is considered the most reliable measure of therapeutic response [3]. VL directly reflects the level of viral replication and provides a more accurate assessment of treatment efficacy compared with immunological markers alone. Therefore, the World Health Organization recommends VL monitoring as the preferred method for evaluating treatment success and identifying virological failure [4, 5, 6]. Viral suppression refers to the reduction of HIV RNA in plasma to low or undetectable levels following ART and is regarded as the primary goal of HIV treatment [7]. Achieving and maintaining viral suppression is associated with improved clinical outcomes, reduced HIV‐related morbidity and mortality, and a lower risk of viral transmission [4, 5, 6, 8]. Studies have shown that viral suppression among PLWH is influenced by multiple factors. Among these, PLWH demographic and clinical characteristics, access to and utilization of healthcare services, treatment‐related factors, and social determinants that affect continuity of care are considered important contributors to virological outcomes [9]. Although several studies have examined factors associated with viral suppression in PLWH, existing evidence suggests that the relative importance and impact of these factors may vary across populations and healthcare systems, particularly in low‐ and middle‐income countries [9]. To the best of our knowledge, limited data are available on factors associated with viral suppression among PLWH in western Iran. Therefore, generating local evidence could help improve the understanding of determinants of virological outcomes and contribute to the optimization of HIV care programs in this region. Therefore, this study was conducted to assess viral suppression status and its associated factors among PLWH who were receiving ART in Kermanshah, western Iran. Considering the cultural and social characteristics of this region, as well as potential differences in access to healthcare services, identifying local factors associated with viral suppression may provide context‐specific evidence that might not be fully captured in studies conducted in other settings. Ultimately, the findings of this study may contribute to improving treatment monitoring and enhancing the quality of care for PLWH. Materials and Methods Study Design and Setting This retrospective study was conducted at the Kermanshah Behavioral Diseases Counseling Center, western Iran, covering the period from 2012 to 2023. Source Population The source population included all medical records of individuals diagnosed with HIV/AIDS who attended the center during the study period (n = 2909 records). Study Population The study population consisted of PLWH with confirmed HIV/AIDS diagnosis who had available and complete clinical records, particularly with documented baseline and follow‐up VL measurements. Inclusion Criteria Confirmed diagnosis of HIV/AIDS and availability of complete medical records, including baseline and follow‐up VL data. Exclusion Criteria Records with missing or incomplete key clinical data, particularly baseline or follow‐up VL measurements, were excluded from the analysis. Sampling Procedure and Sample Size A census sampling approach was used. From the initial 2909 medical records, 710 PLWH met the inclusion criteria and were included in the final analysis after excluding records with incomplete VL data. Study Variables Data on PLWH over the past 11 years were systematically collected based on the study variables, including age, gender, history of incarceration, history of sexual contact, history of drug use, educational level, marital status, route of transmission, clinical stage of the disease, occupation, duration of ART, duration of infection, number of clinic visits, initial VL (prior to treatment), and final VL (after treatment). Although medical records spanning an 11‐year period were reviewed, this study was not designed as a longitudinal time‐series analysis. Instead, for each PLWH, we extracted the baseline VL measured prior to the initiation of ART and the most recent available VL recorded during follow‐up care. Therefore, the analyses were based on two clinically meaningful time points—baseline and follow‐up—rather than repeated measurements across the entire study period. Data Abstraction Procedure Data were systematically extracted from patients' medical records using a standardized extraction form by trained personnel. Quality Control Data cleaning and consistency checks were performed prior to analysis. Records with missing or inconsistent key variables were excluded to ensure data reliability. Statistical Analysis All collected data were analyzed using SPSS software, version 21. Given that the distribution of the VL variable was markedly non‐normal, all statistical procedures were performed using non‐parametric methods. Continuous variables were summarized using the median and interquartile range (IQR). The primary outcome of the study was VL status, defined using a threshold of 200 copies/mL. Participants with VL levels below 200 copies/mL were classified as having viral suppression, whereas those with values of 200 copies/mL or higher were considered non‐suppressed. To assess the robustness of the results, sensitivity analyses were also conducted using alternative cut‐off values of 50 and 1000 copies/mL [7, 10]. The association between secondary VL and continuous variables—including age, duration of infection, duration of treatment, number of clinic visits, duration of ART use, and baseline and follow‐up CD4 counts—was assessed using the Mann–Whitney U‐test. To examine the relationship between secondary VL and binary categorical variables such as sex, history of incarceration, history of sexual contact, history of extramarital contact, and history of drug use, the Chi‐square test was applied. The Chi‐square test was also used to evaluate the association between VL and multi‐category variables, including educational level, marital status, route of transmission, clinical stage, and employment status. However, when more than 20% of cells had expected counts of less than 5, Fisher's exact test (using Monte Carlo estimation for larger tables) was utilized. Multivariable logistic regression analysis was then performed to identify independent factors associated with secondary VL status. Secondary VL status was considered as a binary dependent variable and categorized as suppressed and non‐suppressed. Initially, univariable analyses were conducted to assess the crude association between each independent variable and secondary VL status. Variables associated with secondary VL status in univariable analysis at a significance level of p < 0.20 were considered for inclusion in the multivariable logistic regression model. Prior to fitting the multivariable logistic regression model, multicollinearity was assessed using variance inflation factors (VIFs), and model calibration was evaluated using the Hosmer–Lemeshow goodness‐of‐fit test. A two‐sided p‐value of less than 0.05 was considered statistically significant in the final model. Ethical Considerations The study was approved by the Ethics Committee of Kermanshah University of Medical Sciences (IR.KUMS.MED.REC.1402.231). Due to the retrospective nature of the study and use of anonymized data, informed consent was waived. Results Study Population and Sample Selection In this study, medical records of PLWH attending the Kermanshah Behavioral Diseases Counseling Center between 2012 and 2023 were reviewed using a census‐based approach. During this period, 2909 medical records were identified. After applying inclusion and exclusion criteria, particularly the availability of complete baseline and follow‐up VL data, 710 PLWH were included in the final analysis (Figure 1). Flow diagram of selection of PLWH. Sociodemographic and Clinical Characteristics of Participants Of the 710 participants, 454 (63.9%) were male, and 256 (36.1%) were female. Incarceration history was reported in 339 participants (47.7%), and 380 (53.5%) had a history of drug use. Regarding transmission route, 266 (37.5%) were infected through injecting drug use. Nearly half of the participants were permanently married (47.6%), while others were single, divorced, widowed, or in temporary marriage. In terms of education, most participants had low to moderate educational levels, and 65.4% were unemployed or without a stable occupation (Table 1). Table 1Baseline characteristics of PLWH stratified by viral suppression status (VL < 200 copies/mL) with univariate comparisons.VariableSuppressed, n = 643 (90.6%)Non‐suppressed, n = 67 (9.4%)Total, N = 710Statistics p valueSex, n (%)Male401 (62.4%)53 (79.1%)454 (63.9%)6.670.007* Female242 (37.6%)14 (20.9%)256 (36.1%)Incarceration history, n (%)Yes285 (44.3%)54 (80.6%)339 (47.7%)30.56< 0.001* No358 (55.7%)13 (19.4%)371 (52.3%)History of unsafe sexual behavior, n (%)Yes417 (64.9%)42 (62.7%)459 (64.6%)0.050.789* No226 (35.1%)25 (37.3%)251 (35.4%)History of extramarital contact, n (%)Yes207 (32.2%)25 (37.3%)232 (32.7%)0.510.413* No436 (67.8%)42 (62.7%)478 (67.3%)Addiction history, n (%)Yes323 (50.2%)57 (85.1%)380 (53.5%)28.23< 0.001* No320 (49.8%)10 (14.9%)330 (46.5%)Marital status, n (%)Temporary marriage13 (2.0%)4 (6.0%)17 (2.4%)23.65< 0.001** Permanent marriage321 (49.9%)17 (25.4%)338 (47.6%)Never married146 (22.7%)24 (35.8%)170 (23.9%)Widowed79 (12.3%)5 (7.5%)84 (11.8%)Divorced84 (13.1%)17 (25.4%)101 (14.2%)Occupation, n (%)Laborer16 (2.5%)2 (3.0%)18 (2.5%)16.380.012** High‐risk environment9 (1.4%)0 (0.0%)9 (1.3%)Other occupations202 (31.4%)12 (17.9%)214 (30.1%)Unemployed412 (64.1%)52 (77.6%)464 (65.4%)Student2 (0.3%)0 (0.0%)2 (0.3%)Unknown/Other2 (0.3%)1 (1.5%)3 (0.4%)Clinical stage, n (%)Stage I160 (24.9%)4 (6.0%)164 (23.1%)72.77< 0.001** Stage II458 (71.2%)44 (65.7%)502 (70.7%)Stage III23 (3.6%)15 (22.4%)38 (5.4%)Stage IV2 (0.3%)4 (6.0%)6 (0.8%)Route of transmission, n (%)Injecting drug use223 (34.7%)43 (64.2%)266 (37.5%)24.29< 0.001** Sexual290 (45.1%)13 (19.4%)303 (42.7%)Mother‐to‐child1 (0.2%)0 (0.0%)1 (0.1%)Blood products1 (0.2%)0 (0.0%)1 (0.1%)Unknown125 (19.4%)11 (16.4%)136 (19.2%)Other3 (0.5%)0 (0.0%)3 (0.4%)History of injection drug use, n (%)Yes237 (36.9%)45 (67.2%)282 (39.7%)22.03< 0.001* No406 (63.1%)22 (32.8%)428 (60.3%)Educational status, n (%)Illiterate54 (8.4%)3 (4.5%)57 (8.0%)7.620.106** Elementary166 (25.8%)16 (23.9%)182 (25.6%)Middle209 (32.5%)32 (47.8%)241 (33.9%)High school168 (26.1%)14 (20.9%)182 (25.6%)Higher46 (7.2%)2 (3.0%)48 (6.8%)*Chi‐square test.**Fisher's exact test.John Wiley & Sons, Ltd. Baseline characteristics of PLWH stratified by viral suppression status (VL < 200 copies/mL) with univariate comparisons. Chi‐square test. Fisher's exact test. Viral Suppression Status Among all participants, 643 (90.6%) achieved viral suppression (VL < 200 copies/mL), while 67 (9.4%) were not suppressed (VL ≥ 200 copies/mL). Overall, viral suppression was more frequent among females compared to males. Factors Associated With Viral Suppression (Univariate Analysis) Viral suppression status differed significantly by sex, with a higher proportion of non‐suppression observed among males compared to females (p = 0.007). An incarceration history was strongly associated with viral suppression; non‐suppression was more frequent among those with a prison history (p < 0.001). Similarly, a general history of addiction (p < 0.001) and a specific history of injection drug use (p < 0.001) were significantly associated with poorer viral suppression. Conversely, there was no evidence of a statistically significant association between viral suppression and a history of unsafe sexual behavior (p = 0.789) or a history of extramarital contact (p = 0.413). The results of Fisher's exact test indicated that marital status had a significant association with viral suppression (p < 0.001). Occupation was also significantly associated with viral suppression (p = 0.012). Furthermore, the results of Fisher's exact test revealed a strong association between the latest clinical stage and viral suppression status (p < 0.001), with non‐suppression being disproportionately observed in more advanced clinical stages. The route of HIV transmission was also significantly associated with viral suppression outcomes (p < 0.001). However, educational status was not significantly associated with viral suppression (p = 0.106) (Table 1). Clinical and Laboratory Characteristics Initial and final VL, age, initial and final CD4 count, number of follow‐up visits, duration of ART use, and duration of HIV infection were not normally distributed, so median values and IQR were used to describe these variables. At the beginning of the study, the baseline VL in the suppressed group was 46.5 (IQR: 11.52), while the non‐suppressed group showed a median baseline VL of 43.500 (IQR: 308.491). Regarding the final outcome, the median VL in the suppressed group remained at 0 (IQR: 0), whereas it was significantly higher in the non‐suppressed group at 142.380 (IQR: 393510). CD4 Count and Treatment‐Related Characteristics The analysis of clinical parameters between the viral‐suppressed and non‐suppressed groups revealed differences in several key areas. PLWH in the viral‐suppressed group had higher baseline CD4 counts (median: 337, IQR: 167.50–568.50) compared to the non‐suppressed group (median: 281, IQR: 82.50–546.50; Z = 1.945, p = 0.052). This difference became more pronounced in the last CD4 measurements, where the suppressed group showed higher levels (median: 638, IQR: 436.00–873.50) than the non‐suppressed group (median: 224, IQR: 86.00–465.00; Z = 8.481, p < 0.001). Also, there was a difference in the CD4 count change between the two groups. PLWH with viral suppression demonstrated an increase in their CD4 count (median: 237, IQR: 51.00–492.00) compared to non‐suppressed PLWH, who experienced a median decline in their CD4 count (median: −10, IQR: −110.50–101.00; p < 0.001). Regarding the duration of treatment, the duration of ART use was significantly longer in the viral‐suppressed group (median: 80.56 months, IQR: 56.43–105.59) than in the non‐suppressed group (median: 68.73 months, IQR: 45.36–89.41; Z = 2.714, p = 0.007). In contrast, no differences were observed between the two groups in terms of age (suppressed median: 41, IQR: 36.00–46.00 vs. non‐suppressed median: 41, IQR: 35.00–45.50; p = 0.351) or duration of HIV infection (suppressed median: 112.36 months, IQR: 66.50–185.41 vs. non‐suppressed median: 124.02 months, IQR: 84.88–182.29; p = 0.113). Additionally, the number of follow‐up visits did not differ between the groups (p = 0.472) (Table 2). Table 2Descriptive statistics of continuous clinical parameters by viral suppression status.VariableSuppressed median (Q1–Q3)Non‐suppressed median (Q1–Q3)Total median (Q1–Q3) Z p valueBaseline CD4, median (Q1–Q3)337 (167.50–568.50)281 (82.50–546.50)328 (163.25–561.00)1.9450.052Last CD4, median (Q1–Q3)638 (436.00–873.50)224 (86.00–465.00)599.50 (393.00–853.00)8.481< 0.001CD4 count change, median (Q1–Q3)237 (51.00–492.00)−10 (−110.50–101.00)210 (25.00–464.75)7.500< 0.001Number of follow‐up visits, median (Q1–Q3)46 (27.00–78.00)51 (31.00–74.50)46 (27.00–78.00)−0.7190.472Age (years), median (Q1–Q3)41 (36.00–46.00)41 (35.00–45.50)41 (36.00–46.00)0.9320.351Duration of ART use (months), median (Q1–Q3)80.56 (56.43–105.59)68.73 (45.36–89.41)80.07 (55.66–105.19)2.7140.007Duration of HIV infection (months), median (Q1–Q3)112.36 (66.50–185.41)124.02 (84.88–182.29)114.48 (69.46–185.57)−1.5850.113John Wiley & Sons, Ltd. Descriptive statistics of continuous clinical parameters by viral suppression status. Multivariable Analysis of Factors Associated With Viral Suppression Multicollinearity among the independent variables was assessed using VIFs, and no evidence of problematic multicollinearity was observed (all VIF values < 5). The calibration of the final model was assessed using the Hosmer–Lemeshow goodness‐of‐fit test, which indicated an adequate fit to the data (p = 0.31). Multiple logistic regression was then used to assess factors associated with viral suppression (binary outcome) after adjustment for the variables included in the model. After adjustment, marital status, clinical stage, baseline CD4 count, and follow‐up CD4 count remained significantly associated with viral suppression. In the multivariable logistic regression model, marital status, clinical stage, baseline CD4 count, and follow‐up CD4 count were significantly associated with viral suppression. Using temporary marriage as a reference, PLWH with permanent marriage (OR = 8.170; 95% CI: 1.591–41.948; p = 0.012) and never‐married PLWH (OR = 7.626; 95% CI: 1.427–40.748; p = 0.018) had significantly higher odds of viral suppression. Using Stage I as the reference, Stage II (OR = 0.174; p = 0.003), Stage III (OR = 0.107; p = 0.002), and Stage IV (OR = 0.009; p < 0.001) all had significantly lower odds of viral suppression. Baseline CD4 count was inversely associated (OR = 0.997; p < 0.001) while follow‐up CD4 count was positively associated (OR = 1.005; p < 0.001) with viral suppression. Occupation and route of transmission were not significant after adjustment (Table 3). Table 3Multiple logistic regression analysis of independent predictors of viral suppression (VL < 200 copies/mL) among PLWH.Variable B SEWald p valueOR95% CI for ORSex−1.1150.6982.5550.1100.3280.084–1.287History of incarceration−0.9870.6252.4890.1150.3730.109–1.270History of extramarital sexual contact0.1520.3530.1860.6661.1650.583–2.328Addiction history−1.0460.7022.2180.1360.3510.089–1.392History of drug use (injection)0.2770.5860.2240.6361.3190.418–4.161Baseline CD4 count−0.0030.00119.513< 0.0010.9970.995–0.998Follow‐up CD4 count0.0050.00139.529< 0.0011.0051.004–1.007Duration of ART0.0030.0040.5140.4741.0030.995–1.012Marital status (ref: Temporary marriage)Permanent marriage2.1010.8356.3330.0128.1701.591–41.948Never married2.0320.8555.6450.0187.6261.427–40.748Widowed1.8160.9933.3420.0686.1460.877–43.053Divorced1.3670.8672.4850.1153.9230.717–21.462Clinical stage (ref: Stage I)Stage II−1.7480.5908.7800.0030.1740.055–0.553Stage III−2.2310.7229.5390.0020.1070.026–0.442Stage IV−4.7001.20215.285< 0.0010.0090.001–0.096Occupation (ref: Unemployed)Other occupations0.3680.4130.7960.3721.4450.644–3.243Other/Laborer/Student0.2090.7460.0780.7801.2320.285–5.320Route of transmission (ref: Sexual)Injecting drug use−0.4270.6230.4710.4930.6520.193–2.210Unknown/Other−0.3840.5640.4640.4960.6810.225–2.058John Wiley & Sons, Ltd. Multiple logistic regression analysis of independent predictors of viral suppression (VL < 200 copies/mL) among PLWH. Marital status was significantly associated with viral suppression. Using temporary marriage as the reference category, PLWH with a permanent marriage had significantly higher odds of viral suppression (OR = 8.170; 95% CI: 1.591–41.948; p = 0.012), and those who were never married also had significantly higher odds of viral suppression (OR = 7.626; 95% CI: 1.427–40.748; p = 0.018). The odds of viral suppression were higher among divorced participants compared with the reference group (OR = 3.923; 95% CI: 0.717–21.462; p = 0.115). The association for widowed participants was not statistically significant (OR = 6.146; 95% CI: 0.877–43.053; p = 0.068). The clinical stage was significantly associated with viral suppression (p < 0.001). Using Stage I as the reference category, the odds of viral suppression were significantly lower for PLWH in Stage II (OR = 0.174; 95% CI: 0.055–0.553; p = 0.003), Stage III (OR = 0.107; 95% CI: 0.026–0.442; p = 0.002), and Stage IV (OR = 0.009; 95% CI: 0.001–0.096; p < 0.001). Baseline CD4 count was inversely associated with viral suppression (OR = 0.997; 95% CI: 0.995–0.998; p < 0.001), whereas follow‐up CD4 count was positively associated with viral suppression (OR = 1.005; 95% CI: 1.004–1.007; p < 0.001). Duration of ART was not significantly associated with viral suppression after adjustment (OR = 1.003; 95% CI: 0.995–1.012; p = 0.474). Neither occupation (Other occupations: OR = 1.445, p = 0.372; Other/Laborer/Student: OR = 1.232, p = 0.780) nor route of transmission (Injecting drug use: OR = 0.652, p = 0.493; Unknown/Other: OR = 0.681, p = 0.496) were significantly associated with viral suppression in the adjusted model. Other variables, including sex, incarceration history, history of extramarital sexual contact, addiction history, and history of drug use (injection), were also not significant (p > 0.05) (Table 3). Sensitivity Analyses Sensitivity analyses using alternative viral suppression thresholds (< 50 copies/mL and < 1000 copies/mL) demonstrated consistent results. Across all models, marital status, clinical stage, baseline CD4 count, and follow‐up CD4 count remained the main predictors of viral suppression. For all categorical variables, the first category was used as the reference group. Discussion In this study, most PLWH had viral suppression at the last follow‐up assessment, and several demographic and clinical factors were associated with this outcome. In the present study, sex was associated with viral suppression in the univariate analysis, with a lower rate of viral suppression observed among males. However, this association was not statistically significant after adjustment for clinical and behavioral factors. This finding is partly consistent with Kipp et al., who reported better viral suppression among women, and similarly with Moore et al., who observed a faster virological response in women compared with men [11, 12]. Overall, the observed gender differences in viral suppression are likely explained by behavioral and clinical factors rather than biological sex. Possible explanations include earlier initiation of ART among women, differences in treatment adherence, and higher levels of alcohol consumption among men [13, 14, 15]. A history of incarceration was associated with lower viral suppression in univariate analysis; however, this association did not remain statistically significant in the multivariable model after adjustment. Previous studies have reported that incarceration is linked to poorer adherence and unfavorable virologic outcomes due to structural and psychosocial barriers, including interrupted continuity of care, social stigma, and substance use [16, 17, 18]. Nevertheless, these findings suggest that the observed effect of incarceration may be mediated by other clinical and behavioral factors. Our findings indicate that although PLWH with a history of substance use showed poorer viral suppression in univariate analysis, this association was not statistically significant in the multivariable model after adjustment for potential confounders. This result is partially consistent with previous studies reporting poor adherence to ART, reduced viral suppression, and virologic rebound among individuals who use substances [19, 20]. Overall, substance use may indirectly influence HIV outcomes, primarily through reduced adherence and delayed engagement in care, rather than acting as an independent predictor of viral suppression [21]. Employment status was significantly associated with viral suppression in the univariate analysis; however, this association was no longer significant after adjustment for potential confounding variables in the multivariable model. Nachega et al. reported that employment may promote better adherence to ART [22]. Likewise, a systematic review by Papageorgiou et al. found that socioeconomic disadvantages, including low educational attainment, unstable employment, and limited financial resources, were associated with poorer treatment response and lower rates of viral suppression [23]. Taken together, these findings suggest that while employment may facilitate access to healthcare services and support treatment adherence, it was not an independent predictor of viral suppression in our study after accounting for other relevant factors. Our study found that injection drug use was significantly associated with viral non‐suppression in the univariate analysis; however, this association did not remain significant after adjustment for potential confounders in the multivariable model. This finding is consistent with previous studies. Kerr et al. reported that people who inject drugs initially exhibited lower rates of viral suppression, but the association was attenuated after accounting for behavioral factors, particularly treatment adherence over time [24]. Similarly, Kipkoech et al. demonstrated that retention in HIV care and achievement of viral suppression were lower among people who inject drugs compared with other populations; however, these disparities were largely attributed to structural and behavioral factors, including access to healthcare services and continuity of care [25]. Taken together, these findings suggest that injection drug use may not be an independent predictor of viral suppression, but rather reflects the influence of underlying social and behavioral determinants that affect treatment outcomes. Clinical stage remained associated with viral suppression status after adjustment for the variables included in the model. PLWH in more advanced stages of HIV infection had lower odds of viral suppression compared with those in Stage I. Furthermore, viral suppression was less frequently observed among PLWH with more advanced clinical stages. This finding aligns with previous research; for instance, Salawu et al. reported that individuals in earlier clinical stages (I and II) had better viral suppression outcomes [26]. Moura et al. also reported that early initiation of ART in HIV infection is associated with viral suppression, immune reconstitution, and reduction of the viral reservoir [27]. These findings are consistent with known biological mechanisms, as early ART can preserve CD4+ cells, particularly Th17 cells, and prevent immune system damage, thereby supporting virological control and maintenance of immune function. This underscores the critical importance of early HIV diagnosis and timely initiation of treatment [28]. The findings of this study showed that marital status was significantly associated with viral suppression among PLWH, with both permanently married and never‐married individuals having higher odds of achieving viral suppression compared with those in temporary marriages. This finding is consistent with several cohort studies demonstrating that married individuals or those with a stable partner achieve viral suppression more rapidly than those without a partner [29]. Similarly, a large population‐based study from China reported that married or cohabiting individuals had a lower risk of virologic failure compared with single individuals [30]. However, in many studies, the association between marital status and virologic outcomes was attenuated or became non‐significant after adjustment for factors such as treatment adherence, psychological status, and clinical characteristics, and marital status was interpreted more as a marker of social support and health‐promoting behaviors than as an independent biological determinant of treatment outcomes [31]. Although the present study found an association between marital status and viral suppression, the magnitude of this association was greater than that reported in many previous studies. This discrepancy may be attributable to differences in study population characteristics, the classification of marital status, particularly the use of temporary marriage as the reference category, and variations in social and behavioral factors related to HIV care and treatment. In addition, the temporary marriage group included relatively few participants, which resulted in wide confidence intervals and reduced the precision of the estimated odds ratios. Overall, our findings suggest a possible association between marital status and viral suppression. Further studies with larger numbers of participants across marital status categories are needed to determine whether this association remains consistent in different study populations. The present study showed that baseline CD4 count was inversely associated with viral suppression after adjustment for follow‐up CD4, whereas follow‐up CD4 count was strongly associated with viral suppression status at the last follow‐up assessment. This finding is consistent with the large ART Cohort Collaboration study, which reported that CD4 cell count at 6 months after treatment initiation is a stronger predictor of clinical outcomes than baseline CD4 or changes in CD4 from baseline [32]. Similarly, Hunt et al. demonstrated that even patients with very low pre‐treatment CD4 counts can achieve substantial immune recovery if sustained viral suppression is maintained, indicating that immune restoration is not solely dependent on baseline immune status [33]. In addition, Staszewski et al. reported that the magnitude of CD4 cell increase is strongly influenced by the degree of viral suppression during treatment, with greater CD4 gains observed among patients achieving more effective virologic control [34]. Overall, these findings suggest that immunologic recovery during ART may be more closely related to virologic outcomes than baseline immune status alone, highlighting the importance of treatment response in the management of HIV infection. This study has several limitations. Due to its retrospective design, detailed information on VL testing, ART regimens, regimen modifications, treatment adherence, and HIV drug resistance testing was not consistently available in the medical records. These unmeasured factors may have influenced viral suppression and contributed to residual confounding. Accordingly, the findings should be viewed in light of these limitations. Conclusions Most PLWH achieved viral suppression. Although several demographic and behavioral factors were associated with viral suppression in univariate analyses, these associations diminished after adjustment for potential confounders. In contrast, clinical stage, marital status, and immunological improvement during follow‐up remained significantly associated with viral suppression. These findings highlight the importance of early HIV diagnosis, timely initiation of treatment, and sustained engagement in care to achieve optimal viral suppression. Author Contributions Etrat Javadirad: writing – original draft, writing – review and editing. Mosayeb Rostamian: writing – review and editing. Seyedeh Shadi Vaziri: data curation, investigation. Leila Solouki: formal analysis, statistical analysis. Bahare Andayeshgar: formal analysis, statistical analysis. Sepideh Khodamoradi: data curation, investigation. Roya Chegene Lorestani: writing – original draft, writing – review and editing. Keyghobad Ghadiri: writing – original draft, writing – review and editing. Ethics Statement The study was approved by the Ethical Committee of Kermanshah University of Medical Sciences (ethical code: IR.KUMS.MED.REC.1402.231). Conflicts of Interest The authors declare no conflicts of interest. Transparency Statement Dr. Roya Lorestani affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted.